Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | AGTR1 | P30556 | 4/20 | 0.35 |
| ▸ | AGTR2 | P50052 | 4/20 | 0.35 |
| ▸ | PPARG | P37231 | 3/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.33 |
| ▸ | FDPS | P14324 | 1/20 | 0.33 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.33 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.33 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.32 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.32 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.32 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.32 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.32 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8252426 | 0.92 | ALDH1A1 (0.35) | NPC1CYP2C9RAB9ANPSR1PPARG | |
| SCHEMBL8242374 | 0.86 | AGTR2 (0.39) | AGTR1AGTR2PPARGALOX5AP | |
| SCHEMBL8247457 | 0.85 | HTT (0.41) | CYP2C9NPSR1KDM4EGAA | |
| SCHEMBL16327866 | 0.80 | ALOX5AP (0.38) | AGTR1AGTR2PPARGALOX5AP | |
| SCHEMBL12884201 | 0.79 | CSF1R (0.40) | KDM4E | |
| SCHEMBL8249720 | 0.75 | PLK1 (0.36) | AGTR1AGTR2PPARG | |
| SCHEMBL8249741 | 0.74 | F2 (0.36) | AGTR1AGTR2TDP1S1PR4 | |
| SCHEMBL12884198 | 0.73 | CSF1R (0.42) | NPC1RAB9AALOX5AP | |
| SCHEMBL8283854 | 0.73 | CSF1R (0.53) | — | |
| SCHEMBL12884186 | 0.73 | CYP1A2 (0.51) | CYP2C9NPSR1KDM4ETDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7884215-B2 | 2-substituted benzimidazoles | JANSSEN SCIENCES IRELAND UC (IE) | 2011-02-08 | — | — | US | disclosed |
| US-20100092426-A1 | 2-SUBSTITUTED BENZIMIDAZOLES | JANSSEN SCIENCES IRELAND UC (IE) | 2010-04-15 | — | — | US | disclosed |
| WO-2006136563-A1 | 2-SUBSTITUTED BENZIMIDAZOLES | TIBOTEC PHARMACEUTICALS LTD (IE) | 2006-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100092426-A1 | 2-SUBSTITUTED BENZIMIDAZOLES | HTR4, HRH4, HTR3C | NPC1 2713/4885CYP2C9 896/4885RAB9A 2819/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.